Five-year course of foot ulcers · Single-group study · 2014
How do foot ulcers fare in the five years after shockwave?
In this five-year follow-up of 67 people treated with shockwave for long-standing foot ulcers, 40 of 72 ulcers had healed at one year, and 35 of 61 at five years among people still living. Over those years, 10 people died, most of them with diabetes, and 6 of 57 survivors had an amputation.
- people with long-standing foot ulcers
- 67
- shockwave sessions over 3 weeks
- 6
- years of follow-up
- 5
Good to know: Single-group study; ulcers healed less often, and deaths were more common, in people with diabetes.
Wang CJ, Wu CT, Yang YJ, et al. J Surg Res, 2014 · Read the paper ↗
How this study worked
Conceptual animation: a focused front converges, then spreads. Not to scale. Tap the field to send a pulse.
The treatment
Shockwave
Shockwave, twice a week for 3 weeks
- Pulses
- 500 per session · at least; more for bigger wounds (8 per cm² of wound plus a 1 cm border)
- Strength
- 0.11mJ/mm² setting E2, as reported · 4 per second
- Numbing
- Not mentioned
- Device
- dermaPACE
- Everyone also got
- Ongoing wound and diabetes care as needed
Compared with: No comparison group; people with and without diabetes were compared
Settings are what each study used, not a prescription.
Who took part
67 people with long-standing foot ulcers (72 ulcers): 38 with diabetes and 29 without. At five years, 57 people with 61 ulcers remained.
Side effects
Two people had a burning feeling that went away within 1–2 days. Over five years, 10 people died, 12 needed a skin graft or wound cleaning, and 6 had an amputation; the authors suggest the illness itself played a part.
All the numbers and the full appraisal
Every reported result
The results, in numbers.
67 treated patients with 72 ulcers: 38 people/40 ulcers with diabetes and 29/32 without diabetes. At 5 years 57 survivors/61 ulcers remained.
Participant counts; outcome-specific denominators remain in each panel.
Completely healed ulcers1 reported outcome
Completely healed ulcers
Completely healed ulcers ulcers
Closure at one year: 40/72 ulcers. Ulcers, not people; all had received ESWT.
Analysis details and source
Closure at one year: 40/72 ulcers. Ulcers, not people; all had received ESWT.
Completely healed ulcers among survivors1 reported outcome
Completely healed ulcers among survivors
Completely healed ulcers among survivors ulcers
Closure at five years: 35/61 ulcers among survivors. Ten deaths excluded from late wound denominator.
Analysis details and source
Closure at five years: 35/61 ulcers among survivors. Ten deaths excluded from late wound denominator.
All-cause mortality1 reported outcome
All-cause mortality
All-cause mortality participants
Nine of 38 diabetics and 1/29 nondiabetics died; observational comparison.
Analysis details and source
Nine of 38 diabetics and 1/29 nondiabetics died; observational comparison.
Amputation among survivors1 reported outcome
Amputation among survivors
Amputation among survivors participants
Reported denominator excludes deaths; not a treatment-related harm estimate.
Analysis details and source
Reported denominator excludes deaths; not a treatment-related harm estimate.
Ulcer closure at three months1 reported outcome
Ulcer closure at three months
Ulcer closure at three months ulcers
27/72 ulcers closed: 8/40 in the diabetes subgroup and 19/32 without diabetes. All received shockwaves; this is not an untreated comparison.
Analysis details and source
27/72 ulcers closed: 8/40 in the diabetes subgroup and 19/32 without diabetes. All received shockwaves; this is not an untreated comparison.
Laser Doppler perfusion trajectory1 reported outcome
Laser Doppler perfusion trajectory
Laser Doppler perfusion trajectory reported laser Doppler instrument units
Diabetes: baseline 0.50±0.20, six weeks 0.57±0.21, one year 0.65±0.28, five years 0.11±0.10. Without diabetes: 0.49±0.29, 0.55±0.25, 0.67±0.30 and 0.28±0.22, respectively. Five-year subgroup p=.04. These instrument measurements are not direct clinical benefit; no untreated control was included.
Analysis details and source
Diabetes: baseline 0.50±0.20, six weeks 0.57±0.21, one year 0.65±0.28, five years 0.11±0.10. Without diabetes: 0.49±0.29, 0.55±0.25, 0.67±0.30 and 0.28±0.22, respectively. Five-year subgroup p=.04. These instrument measurements are not direct clinical benefit; no untreated control was included.
How treatment was delivered
dermaPACE, E 2 reported 0.11 mJ/mm², 4 Hz, minimum 500 impulses or expanded wound area× 8; twice/week× 3 weeks. Source energy differs from 2011 report; do not harmonize. Anesthesia not stated.
Two transient burning sensations resolved within 1–2 days. By five years, 10 patients had died, 12 had needed a skin graft or debridement and 6 had an amputation; the authors suggest the natural course of the disease may have contributed. Causes of death are not reported, and the study cannot attribute prevention or causation to ESWT.
No standard-care concurrent control; survivorship changes denominators. The historical controls (149 patients with diabetic foot ulcers treated in 2004) are not described by case mix or follow-up time. Multiple ulcer observations may be correlated. QOL timing/comparator selection unclear. Wang disclosed Sanuwave advisory role; Chang Gung grants funded work. Table 3 prints 12/72 as 6.7%, although the raw fraction is 16.7%. The text describes 12 patients receiving skin grafts while wound tables use ulcer denominators; these units cannot be interchanged.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- No standard-care concurrent control; survivorship changes denominators. The historical controls (149 patients with diabetic foot ulcers treated in 2004) are not described by case mix or follow-up time. Multiple ulcer observations may be correlated. QOL timing/comparator selection unclear. Wang disclosed Sanuwave advisory role; Chang Gung grants funded work. Table 3 prints 12/72 as 6.7%, although the raw fraction is 16.7%. The text describes 12 patients receiving skin grafts while wound tables use ulcer denominators; these units cannot be interchanged.
Source-linked critical reading
Uncontrolled studies
Technical source record
Full source read: body, methods, results, all six tables (the article has no figures), discussion and disclosures. The article lists no supplementary material.
Over five years, deaths, operations and amputations occurred, more often with diabetes.
How durable was ulcer healing five years after shockwave treatment, and how did outcomes differ by diabetes status?
Uncontrolled longitudinal follow-up of 67 treated patients with 72 ulcers, comparing diabetes subgroups; 57 survivors with 61 ulcers remained at five years.
67 treated patients with 72 ulcers: 38 people/40 ulcers with diabetes and 29/32 without diabetes. At 5 years 57 survivors/61 ulcers remained.
All received six ESWT treatments and necessary ongoing wound/diabetes care.
Diabetic versus nondiabetic prognosis; historical diabetic controls and a separate HBOT QOL sample were not randomized concurrent controls.
Wound status was classified at three months, one year and five years. Laser Doppler measurements assessed perfusion at baseline, six weeks, one year and five years. Mortality and amputation were recorded separately from ulcer-level healing; late healing denominators exclude those who died.
Complete healing 40/72 at 1 year and 35/61 at 5 years; the later denominator excludes 10 deaths. Diabetes 13/30 versus nondiabetes 22/31 ulcers healed at 5 years. Perfusion gains at 1 year declined by 5 years. Six of 57 survivors underwent amputation.
Two transient burning sensations resolved within 1–2 days. By five years, 10 patients had died, 12 had needed a skin graft or debridement and 6 had an amputation; the authors suggest the natural course of the disease may have contributed. Causes of death are not reported, and the study cannot attribute prevention or causation to ESWT.
No standard-care concurrent control; survivorship changes denominators. The historical controls (149 patients with diabetic foot ulcers treated in 2004) are not described by case mix or follow-up time. Multiple ulcer observations may be correlated. QOL timing/comparator selection unclear. Wang disclosed Sanuwave advisory role; Chang Gung grants funded work. Table 3 prints 12/72 as 6.7%, although the raw fraction is 16.7%. The text describes 12 patients receiving skin grafts while wound tables use ulcer denominators; these units cannot be interchanged.
Describes prognosis after treatment, not sustained causal benefit. Booster therapy is a hypothesis, not tested here.
A controlled long-term study should jointly report healing, recurrence, amputation and death, account for multiple ulcers and competing mortality, and follow every originally enrolled patient.
Read the original article.
Long-term outcomes of extracorporeal shockwave therapy for chronic foot ulcers
Wang CJ, Wu CT, Yang YJ, Liu RT, Kuo YR. · J Surg Res · 2014
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →